



**TOTAL DIRECT COMPENSATION
CEO-Current Year**

Company	Title(s)	Base	Variable Cash	Time-Based		Performance Based	Other LTIP	Total Direct Comp	Value Realized From			Notes
				SAR/Option Grant	Restricted Stock	LTIP			Options Vesting	Stock Vesting	LTIP Payouts	
ABIOMED	Chair, CEO, President	368,750	371,700	806,391	1,746,562	1,478,864		4,772,267	272,398	818,084		
Alphatec Spine	CEO, President	362,212	116,157	324,330				802,699		774,525		
AngioDynamics	CEO, President	382,650	130,039	514,794				1,027,483		20,135		
ATS Medical	Chair, CEO, President	350,000	217,000		1,005,000			1,572,000		169,194		
Cardiac Science	CEO, President	376,923	180,000		270,900			827,823	27,712			
CryoLife	Chair, CEO, President	618,228	422,958	276,038	96,263			1,413,487	455,489			
Hansen Medical	CEO	350,000		1,749,900				2,099,900				
Micrus Endovascular	Chair, CEO	428,060	25,684	159,376				613,120				
Osteotech	CEO, President	400,000	24,000		20,907	48,760		493,667		400,674		
Replidyne	CEO, President	350,000		122,760				472,760				
Stereotaxis	CEO, President	400,000	50,000	440,000		98,785		988,785				
Vascular Solutions	CEO	330,000	103,488		135,675			569,163	178,500	71,000		
	COUNT	12	10	8	6	3	0	12	4	6	0	
	LOWEST	\$330,000	\$24,000	\$122,760	\$20,907	\$48,760	N/A	\$472,760	\$27,712	\$20,135	N/A	
	10TH PERCENTILE	350,000	25,516	N/A	N/A	N/A	N/A	501,217	N/A	N/A	N/A	
	25TH PERCENTILE	350,000	63,372	N/A	N/A	N/A	N/A	602,131	N/A	N/A	N/A	
	50TH PERCENTILE	372,837	123,098	382,165	203,288	98,785	N/A	908,304	225,449	284,934	N/A	
	75TH PERCENTILE	400,000	207,750	N/A	N/A	N/A	N/A	1,453,115	N/A	N/A	N/A	
	90TH PERCENTILE	425,254	376,826	N/A	N/A	N/A	N/A	2,047,110	N/A	N/A	N/A	
	HIGHEST	\$618,228	\$422,958	\$1,749,900	\$1,746,562	\$1,478,864	N/A	\$4,772,267	\$455,489	\$818,084	N/A	
	AVERAGE	\$393,068	\$164,102	\$549,198	\$545,884	\$542,136	N/A	\$1,304,429	\$233,524	\$375,602	N/A	



OFFICER COMMENTS

Chief Financial Officer-Current Year

COMPANY	NAME	TITLE(S)	NOTES
Spectranetics	Guy Childs	VP, CFO	¹ Options have an exercise price of \$2.74, the closing sale price of the Company's common stock on December 8, 2008, and will vest upon the achievement of a \$9 share price, based on a 10-day average closing price of Spectranetics common stock.
